Agilon Health (AGL) Stock Forecast & Price Target

Agilon Health is viewed positively because its latest quarterly results showed strong operating leverage, with 3Q26 revenue of $1.52 billion up 6% year over year, medical margin of 11.5% versus an 8.5% guide, and adjusted EBITDA of $64 million versus break-even, driven by favorable risk adjustment, stronger payer contracting, and better cost trends. The company’s FY26 AEBITDA guidance midpoint was lifted sharply to $150 million, nearly double the prior midpoint, while management expects further upside from high-risk patient management, ACO expansion, and improved contracting that could support at least $170 million of AEBITDA in FY27. Its balance sheet also appears solid, with $257 million of cash and $32 million of debt at 6/30, and year-end cash expected to be at least $125 million with FY27 expected to be cash positive.

Agilon Health is burdened by a business model that depends heavily on payors for membership attribution, reporting accuracy, claims payments, and risk adjustment factors, creating meaningful reimbursement and cash flow uncertainty. Its ability to identify and develop successful new markets is still unproven, while intense competition and industry consolidation can pressure physician-partnership expansion and limit scale benefits. As a result, the company faces elevated risk in achieving and maintaining profitability, with the core platform exposed to operational execution setbacks and margin compression.